Adaptive Biotechnologies Corporation
NASDAQ:ADPTBiotechnology
+$0.61 today
- Market cap
- $4.61B
- Beta
- 2.15
- P/E (TTM)
- -54.5
- EPS (TTM)
- -$0.32
Volume 2.21M
Average 1.94M
ADPT Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
Adaptive Biotechnologies CorporationNASDAQ: ADPT
Stock-Based Compensation · Q2 FY2026 · quarter ended Jun 2026
Stock-based compensation dips below year-ago levels
Q2 FY2026 stock-based compensation of $11.12M fell 16.8% year over year, behind the +36.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 6.8% from the prior quarter.
Context
- Stock-based compensation amounted to 18.6% of revenue in FY2025, down 11.4 pp from a year earlier.
- Stock-based compensation increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -16.8% toward the trailing-twelve-month pace of +36.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 51.48M USD
- Year-over-year change
- -4.0%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 51.48M | -4.0% |
| FY2024 | 2024-12-31 | 53.61M | — |
| FY2023 | 2023-12-31 | 0 | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Stock-Based Compensation vs competitors
How ADPT compares with its peers on the latest reported figures
- ADPT's LTM Jun 2026 stock-based compensation of $35.77M is the 6th largest of the 10 companies compared; the peer median is $50.41M.
- Its year-over-year change of +36.6% is the 4th highest of 10, against a peer median of +26.9%.
- Stock-based compensation amounts to 11.6% of revenue for ADPT, versus a peer median of 9.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $75.24M | +14.6% | +39.7% | 13200.2% | |
| LTM Sep 2026 | $66.79M | +91.9% | +45.8% | 9.8% | |
| LTM Jun 2026 | $58.29M | -12.7% | +2.3% | 13.0% | |
IRONDisc Medicine, Inc. | LTM Sep 2026 | $50.54M | +76.5% | +154.3% | — |
| LTM Mar 2026 | $50.41M | +30.4% | +58.3% | 22.4% | |
| LTM Jun 2026 | $35.77M | +36.6% | — | 11.6% | |
| LTM Mar 2026 | $25.19M | +26.9% | +46.3% | 4.2% | |
| LTM Jun 2026 | $25.03M | +73.0% | +248.9% | — | |
| LTM Jun 2026 | $12.73M | -111.5% | +3.8% | 8.2% | |
| LTM Sep 2026 | $7.7M | -87.8% | — | 0.6% | |
| Peer median (excluding ADPT) | $50.41M | +26.9% | +46.1% | 9.8% | |
Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (207.28M) | (200.19M) | (225.25M) | (159.6M) | (59.5M) |
| Depreciation & Amortization | 13.95M | 20.92M | 22.23M | 19.26M | 17.83M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 53.61M | 51.48M |
| Change in Working Capital | (56.82M) | (71.55M) | (46.18M) | (17.45M) | (57.77M) |
| Accounts Receivables | (7.36M) | (22.65M) | 2.03M | (3.74M) | (8.65M) |
| Inventory | (5.2M) | 817K | (2.84M) | 1.94M | (998K) |
| Accounts Payables | 3.94M | 7.11M | (5.41M) | 671K | 665K |
| Other Working Capital | (48.19M) | (56.83M) | (39.97M) | (16.32M) | (48.79M) |
| Other Non-Cash Items | 57.42M | 66.87M | 92.88M | 8.97M | 1.96M |
| Operating Cash Flow | (192.73M) | (183.95M) | (156.32M) | (95.21M) | (45.99M) |
| Capital Expenditures | (61.75M) | (16.35M) | (10.7M) | (3.66M) | (2.96M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (316.54M) | (278.78M) | (429.56M) | (244.26M) | (181.71M) |
| Sales of Investments | 559.5M | 298.03M | 569.9M | 325.71M | 222.62M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 181.21M | 2.91M | 129.65M | 77.79M | 37.95M |
| Debt Repayment | 0 | 124.38M | 0 | 0 | 0 |
| Common Stock Issued | 26.72M | 7.89M | 2.25M | 241K | 30.4M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 429K | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 27.15M | 132.26M | 2.25M | 241K | 30.4M |
| Effect of Forex Changes | 0 | (260K) | (534K) | 0 | 0 |
| Net Change in Cash | 15.63M | (49.04M) | (24.97M) | (17.18M) | 22.37M |
| Free Cash Flow | (254.47M) | (200.29M) | (167.02M) | (98.88M) | (48.95M) |
Adaptive Biotechnologies Corporation
NASDAQ:ADPT
Intrinsic Alpha fair value
Locked
Current Price
$28.46
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.